Amgen Inc. (NASDAQ:AMGN) was the recipient of a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 9,412,565 shares, a growth of 29.5% from the August 31st total of 7,267,419 shares. Currently, 1.3% of the company’s shares are sold short. Based on an average daily volume of 3,016,948 shares, the short-interest ratio is currently 3.1 days.

AMGN has been the topic of a number of recent analyst reports. Cann restated a “buy” rating on shares of Amgen in a research report on Monday, August 28th. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $203.00 price target on shares of Amgen in a research report on Thursday, September 7th. Deutsche Bank AG initiated coverage on shares of Amgen in a research report on Friday, June 23rd. They issued a “hold” rating and a $172.00 price target on the stock. William Blair restated a “market perform” rating on shares of Amgen in a research report on Monday, June 26th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $195.00 price target on shares of Amgen in a research report on Monday, July 17th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the stock. Amgen currently has a consensus rating of “Buy” and a consensus price target of $188.41.

Shares of Amgen (NASDAQ AMGN) opened at 186.45 on Friday. The stock has a 50 day moving average of $175.99 and a 200 day moving average of $169.31. Amgen has a 1-year low of $133.64 and a 1-year high of $191.10. The company has a market cap of $136.05 billion, a price-to-earnings ratio of 16.98 and a beta of 1.35.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating the consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.84 earnings per share. On average, equities analysts forecast that Amgen will post $12.57 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were issued a dividend of $1.15 per share. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.47%. Amgen’s payout ratio is presently 41.93%.

Several large investors have recently modified their holdings of AMGN. Naples Global Advisors LLC increased its holdings in shares of Amgen by 2.2% during the first quarter. Naples Global Advisors LLC now owns 16,942 shares of the medical research company’s stock valued at $2,780,000 after acquiring an additional 365 shares in the last quarter. V Wealth Management LLC increased its holdings in shares of Amgen by 45.7% during the first quarter. V Wealth Management LLC now owns 13,125 shares of the medical research company’s stock valued at $2,148,000 after acquiring an additional 4,117 shares in the last quarter. Hollencrest Securities LLC bought a new position in shares of Amgen during the first quarter valued at $562,000. Concorde Asset Management LLC increased its holdings in shares of Amgen by 5.9% during the first quarter. Concorde Asset Management LLC now owns 2,054 shares of the medical research company’s stock valued at $337,000 after acquiring an additional 114 shares in the last quarter. Finally, Ferguson Wellman Capital Management Inc. increased its holdings in shares of Amgen by 0.9% during the first quarter. Ferguson Wellman Capital Management Inc. now owns 193,008 shares of the medical research company’s stock valued at $31,667,000 after acquiring an additional 1,677 shares in the last quarter. Hedge funds and other institutional investors own 78.10% of the company’s stock.

WARNING: “Amgen Inc. (AMGN) Short Interest Up 29.5% in September” was originally published by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/amgen-inc-amgn-short-interest-up-29-5-in-september/1599733.html.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.